D1 Receptor PAM Derivatives to Avoid Dopamine Overstimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dopaminergic CNS disorders such as Parkinson's disease, Alzheimer's disease, Schizophrenia, and ADHD lack effective and safe alternatives to directly or indirectly modulate dopamine receptors, leading to issues like overstimulation, tolerance, and undesirable side effects.
Innovation Solution
Development of selective dopamine D1 receptor positive allosteric modulators (D1 PAMs) that enhance dopamine receptor activity without constant activation, using phenyl-3,4-dihydroisoquinolin-2(1H)-yl-ethan-1-one derivatives with specific configurations to improve cognitive and motor functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D1 agonists are used to activate D1 receptors, then D1 receptor activity is increased, but overstimulation and rapid tolerance development occur
Solution Approach 1:
The patent introduces a positive allosteric modulator as an intermediary substance that indirectly enhances D1 receptor activity rather than directly activating it. The PAM binds to an allosteric site on the D1 receptor, inducing a conformational change that increases the receptor's affinity and responsiveness to endogenous dopamine. This intermediary mechanism allows modulation of D1 signaling without the overstimulation and tolerance issues associated with direct agonists.
2Reliability
If D1 agonists are administered at higher doses to enhance therapeutic effect, then D1 receptor activation is increased, but bell-shaped dose-response relationship and side effects increase
Solution Approach 1:
The patent employs a dynamic modulation approach where the PAM's effect is dependent on the presence and concentration of endogenous dopamine. The allosteric modulator does not constitutively activate the receptor but rather dynamically enhances signaling only when dopamine is bound, creating a dopamine-dependent amplification effect. This dynamic mechanism prevents the bell-shaped dose-response and side effects seen with direct agonists at high doses.
3Reliability
If direct dopamine receptor modulation is used, then dopaminergic activity is enhanced, but impulse control disorders, psychosis, and cognitive worsening occur
Solution Approach 1:
The patent applies local quality enhancement by using a D1-selective positive allosteric modulator that specifically targets D1 receptors in cortical and subcortical regions without significantly affecting D2 receptors. The PAM locally amplifies D1 signaling in dopamine-rich brain regions, providing region-specific modulation that enhances dopaminergic activity while avoiding the D2-mediated side effects such as impulse control disorders and psychosis associated with non-selective agonists.
Data Source
AI summary
The invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, to treat certain symptoms of dopaminergic CNS disorders including Parkinson's disease, Schizophrenia, ADHD or Alzheimer's disease.